Immunome IMNM Ratios (2019-2026)

NASDAQ IMNM
$26.75 -0.41 (-1.51%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Immunome Quarterly Ratios

Periods 26 quarters
Latest Jun 2026

Immunome ratios data for the quarter ended Jun 2026. These financial ratios cover 26 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Sep2019 Dec2019 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
EBT Margin
-189.13%-135.42%-129.96%-2,473.94%-12,857.05%-1,692.43%-1,736.15%-3,030.31%-1,525.50%-1,157.61%
EBIT Margin
-189.13%-135.42%-129.96%-2,473.94%-12,857.05%-1,692.43%-1,736.15%-3,030.31%-1,525.50%-1,157.61%
EBITDA Margin
-189.13%-135.42%-129.96%-2,473.94%-12,857.05%-1,692.43%-1,736.15%-3,030.31%-1,525.50%-1,157.61%
Operating Margin
-189.13%-135.42%-129.96%-2,473.94%-12,857.05%-1,692.43%-1,736.15%-3,030.31%-1,525.50%-1,157.61%
Net Margin
-189.13%-135.42%-121.88%-2,421.17%-12,857.05%-1,692.43%-1,736.15%-3,030.31%-1,525.50%-1,157.61%
FCF Margin
1,013.11%-138.19%-242.64%-465.45%-1,295.82%-1,088.87%-1,227.01%-1,577.28%-1,938.48%-1,252.95%
Efficiency
Assets AverageAssets Avg.
63.35M60.24M52.83M43.37M34.78M27.30M36.08M44.77M67.30M120.85M234.15M307.98M276.56M248.57M291.47M319.49M297.83M491.28M651.49M592.59M
Invested CapitalInvested Cap.
Asset Utilization RatioAsset Util.
0.120.050.040.040.040.040.040.030.010.01
Leverage & Solvency
Interest Coverage RatioInterest Cover
Debt Ratio
Times Interest Earned
Valuation
Price to EarningsP/E
-38.14-19.99-5.91-4.36-5.88-3.44-13.61-16.72-23.45-2.29-11.14-18.15-17.48-8.25-13.11-17.41-17.86-25.75-41.72-30.75
Price to SalesP/S
25.7422.6428.5855.500.00M307.18303.56250.03200.00201.55
Price to BookP/B
5.373.261.821.292.331.614.3910.3316.771.775.162.864.113.781.913.014.072.964.204.58
Enterprise Value
238.23M107.72M26.00M4.28M26.77M6.48M16.42M58.09M11.25M74.19M1,163.53M447.81M643.20M467.27M267.89M541.14M801.25M1,222.82M1,892.36M1,882.92M
EV to EBIT
-30.85-13.73-2.23-0.48-3.14-0.83-3.67-10.06-2.43-0.78-8.79-11.19-12.73-5.63-6.00-11.64-13.32-16.78-31.89-24.10
EV to EBITDA
-30.85-13.73-2.23-0.48-3.14-0.83-3.67-10.06-2.43-0.78-8.79-11.19-12.73-5.63-6.00-11.64-13.32-16.78-31.89-24.10
Market Capitalization
294.47M156.95M68.88M38.93M53.85M26.80M60.85M96.51M101.89M212.33M1,473.25M726.17M883.37M684.57M585.21M809.22M1,073.89M1,876.30M2,475.06M2,402.93M
Price to FCFP/FCF
-70.60-23.02-10.79-4.73-7.11-3.972.54-16.38-11.78-11.92-110.49-28.21-24.74-15.85-10.32-16.09-25.80-36.12-40.15-37.62
EV to FCF
-57.12-15.80-4.07-0.52-3.54-0.960.69-9.86-1.30-4.17-87.26-17.40-18.01-10.82-4.72-10.76-19.25-23.54-30.70-29.48
EV to CFO
-57.47-15.83-4.08-0.53-3.54-0.970.68-10.25-1.31-4.25-104.17-19.14-18.83-11.11-5.05-10.95-19.78-25.50-32.27-30.52
Return Ratios
Return on Sales [ROS]ROS
-189.13%-135.42%-129.96%-2,473.94%-12,857.05%-1,692.43%-1,736.15%-3,030.31%-1,525.50%-1,157.61%-2,419.90%-3,228.83%-5,947.90%
Return on Capital Employed [ROCE]ROCE
-38.56%-49.90%-76.44%-104.00%-134.82%-184.83%-264.18%-144.51%-51.29%-110.61%-116.71%-101.31%-133.94%-157.42%-83.68%-75.72%-87.92%-50.22%-38.27%-48.57%
Return on Assets [ROA]ROA
-33.83%-41.84%-62.39%-83.34%-106.25%-135.19%-82.37%-59.33%-33.68%-90.63%-101.37%-88.18%-114.80%-123.02%-74.84%-70.30%-78.64%-45.62%-36.66%-45.64%